Abstract
Background
The clinical impact of salvage surgery after chemotherapy on cancer survival of patients with metastatic urothelial carcinoma is controversial. We aimed to verify the clinical role of salvage surgery by analyzing the long-term outcome in patients with urothelial carcinoma treated by chemotherapy.
Methods
Between 2003 and 2010 at a single institution, 31 of 47 patients (66%) with metastatic urothelial carcinoma showed objective responses (CR in 4, PR in 27) after multiple courses of cisplatin/gemcitabine/paclitaxel-based chemotherapy, and a cohort of patients with partial response (PR) were retrospectively enrolled. Twelve (10 male and 2 female, median age 64.0 years) of 27 patients with PR underwent salvage surgeries after the chemotherapy: metastatectomy of residual lesions (10 retroperitoneal lymph nodes, 2 lung), and 6 radical surgeries for primary lesions as well. Progression-free survival and overall patient survival rates were analyzed retrospectively and compared with those of patients without salvage surgery.
Results
All 12 patients achieved surgical CR. Pathological findings of metastatic lesions showed viable cancer cells in 3 patients. In univariate analysis, sole salvage surgery affected overall survival in 27 patients with PR to the chemotherapy (P = 0.0037). Progression-free survival and overall survival rates in patients with salvage surgery were better than those in 15 PR patients without the surgery (39.8 vs. 0%, and 71.6 vs. 12.1% at 3 years, P = 0.01032 and 0.01048; log-rank test).
Conclusions
Salvage surgery for patients with residual tumor who achieve partial response to chemotherapy could have a possible impact on cancer survival.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Roth BJ, Bajorin DF (1995) Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world. J Urol 153:894–900
Sternberg CN (1995) The treatment of advanced bladder cancer. Ann Oncol 6:113–126
Loehrer PJ Sr, Einhorn LH, Elson PJ et al (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10:1066–1073
Logothetis CJ, Dexeus FH, Finn L et al (1990) A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8:1050–1055
Von der Maase H, Hansen SW, Roberts JT et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 17:3068–3077
Siefker-Radtke AO, Millikan RE, Tu SM et al (2002) Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol 20:1361
Cowles RS, Johnson DE, McMurtrey MJ (1982) Long-term results following thoracotomy for metastatic bladder cancer. Urology 20:390–392
Dodd PM, McCaffrey JA, Herr HW et al (1999) Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. J Clin Oncol 17:2546–2552
Miller RS, Freiha FS, Reese JH et al (1993) Cisplatin, methotrexate and vinblastine plus surgical restaging for patients with advanced transitional cell carcinoma of the urothelium. J Urol 150:65–69
Herr HW, Donat SM, Bajorin DF (2001) Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. J Urol 165:811–814
Abe T, Shinohara N, Harabayashi T et al (2007) Impact of multimodal treatment on survival in patients with metastatic urothelial cancer. Eur Urol 52:1106–1113
Sweeney P, Millikan R, Donat M et al (2003) Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder? J Urol 169:2113–2117
Siefker-Radtke AO, Walsh GL, Pisters LL et al (2004) Is there a role for surgery in the management of metastatic urothelial cancer? The M.D. Anderson experience. J Urol 171:145–148
Lehmann J, Suttmann H, Albers P et al (2009) Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05). Eur Urol 55:1293–1299
Dimopoulos MA, Finn L, Logothetis CJ (1994) Pattern of failure and survival of patients with metastatic urothelial tumors relapsing after cis-platinum-based chemotherapy. J Urol 151:598–600
Bellmunt J, Albanell J, Paz-Ares L, Climent MA, González-Larriba JL, Carles J, de la Cruz JJ, Guillem V, Díaz-Rubio E, Cortés-Funes H, Baselga J (2002) Spanish Oncology Genitourinary Group. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer 95(4):751–757
Herr HW (2009) Is metastatectomy for urothelial carcinoma worthwhile? Eur Urol 55:1300–1301
Childs MA, Wood CG, Spiess PE et al (2010) Early results of chemotherapy with retroperitoneal lymph node dissection for isolated retoroperitoneal recurrence of upper urinary tract urothelial carcinoma after nephroureterectomy. Can J Urol 17:5184–5189
Otto T, Krege S, Suhr J et al (2001) Impact of surgical resection of bladder cancer metastases refractory to systemic therapy on performance score: a phase II trial. Urology 57:55–59
Conflict of interest
No author has any conflict of interest.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Bekku, K., Saika, T., Kobayashi, Y. et al. Could salvage surgery after chemotherapy have clinical impact on cancer survival of patients with metastatic urothelial carcinoma?. Int J Clin Oncol 18, 110–115 (2013). https://doi.org/10.1007/s10147-011-0350-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-011-0350-z